drug
(berahyaluronidase alfa + pembrolizumab)
Marketedupdated 6mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5indications
investigational
NSCLCMelanoma
all catalysts(5)
approval · 5
Sep 19, 2025
approval
KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
(berahyaluronidase alfa + pembrolizumab)
→
Sep 19, 2025
approval
KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
(berahyaluronidase alfa + pembrolizumab)
→
Nov 21, 2025
approval
KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
(berahyaluronidase alfa + pembrolizumab)
→
Feb 10, 2026
approval
KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
(berahyaluronidase alfa + pembrolizumab)
→
Apr 6, 2026
approval
KEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval
(berahyaluronidase alfa + pembrolizumab)
→
News(7)
- Merck looks ahead to ‘another year of investment’ as Keytruda cliff loomsOn its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertensi…biospace · 18d ago
- Merck outlines 2027 as ‘another year of investment’ despite recent clinical winsEven as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial expansions over near-term margin growth, hoping to strengthen its long-term…fiercebiotech · 18d ago
- Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earningsBellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.biospace · 1mo ago
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trialA Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.biopharma_dive · 1mo ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 3mo ago
- Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missThe anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…biospace · 3mo ago
- Medicare drug price rule may target under-the-skin Keytruda and OpdivoFor 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.biopharma_dive · 5mo ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that